![]() |
|
|
Vol. 293, Issue 1, 275-280, April 2000
Lilly Neuroscience (D.A.S., S.L.G., D.R.G.) and Lilly Endocrine
Research (M.L.H.), Lilly Research Laboratories, Eli Lilly and Co.,
Lilly Corporate Center, Indianapolis, Indiana
1229U91 (GW1229 or GR231118)
[lle,Glu,Pro,Dpr,Tyr, Arg,Leu,Arg,Tyr-NH2)2 cyclic
(2,4'),(2'4)-diamide] has been reported by several research groups to
be a potent antagonist at the Y1 neuropeptide Y (NPY) receptor subtype.
However, 1229U91 also displaces 125I-peptide YY (PYY) with
high affinity from the Y4 subtype. Previously, we reported that 1229U91
had full agonist properties for the Y4 receptor. To characterize the
pharmacological properties of 1229U91 directly, we had it
radioiodinated with the chloromine-T method. 125I-1229U91
bound to cell lines expressing the human Y1 and Y4 receptors with high
affinity. The Kd and
Bmax for 125I-1229U91 binding to
Y1 were 14.9 pM and 1458 fmol/mg protein, respectively. The Y4 receptor
bound 125I-1229U91 with a Kd of
12.5 pM and a Bmax of 1442 fmol/mg protein. When competing 125I-1229U91 binding from Y1 and Y4
receptors, a similar rank order of potency was observed: 1229U91 > [Leu31,Pro34]-NPY
[Leu31,Pro34]-PYY > PYY
NPY > NPY(2-36) > PYY(3-36). Pancreatic polypeptide (PP)
potently displaced 125I-1229U91 from the Y4 receptor, but
displayed little affinity for Y1. In autoradiographic studies with rat
brain sections, 125I-1229U91 bound with a distribution
similar to that reported for the Y1 receptor when localized with
125I-[Leu31,Pro34]-PYY. Brain
regions exhibiting binding sites for 125I-PP were not
detected with this radioligand. Those include the interpeduncular
nucleus and the periventricular nucleus of the hypothalamus.
Furthermore, 125I-labeled rat PP was not displaced from
these areas with 10 nM 1229U91. Thus, 125I-1229U91 is a
high affinity Y1 and Y4 radioligand and binds with a distribution in
the rat brain consistent with the localization of the Y1 receptor.
This article has been cited by other articles:
![]() |
M. M. Kamiji and A. Inui Neuropeptide Y Receptor Selective Ligands in the Treatment of Obesity Endocr. Rev., October 1, 2007; 28(6): 664 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. R. Tough, N. D. Holliday, and H. M. Cox Y4 Receptors Mediate the Inhibitory Responses of Pancreatic Polypeptide in Human and Mouse Colon Mucosa J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 20 - 30. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Dumont, E. Moyse, A. Fournier, and R. Quirion Evidence for the Existence of an Additional Class of Neuropeptide Y Receptor Sites in Rat Brain J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 99 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Acuna-Goycolea, N. Tamamaki, Y. Yanagawa, K. Obata, and A. N. van den Pol Mechanisms of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Inhibition of Identified Green Fluorescent Protein-Expressing GABA Neurons in the Hypothalamic Neuroendocrine Arcuate Nucleus J. Neurosci., August 10, 2005; 25(32): 7406 - 7419. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Berglund, P. A. Hipskind, and D. R. Gehlert Recent Developments in Our Understanding of the Physiological Role of PP-Fold Peptide Receptor Subtypes Experimental Biology and Medicine, March 1, 2003; 228(3): 217 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Campbell, M. S. Smith, S. E. Allen, B. E. Grayson, J. M. H. ffrench-Mullen, and K. L. Grove Orexin Neurons Express a Functional Pancreatic Polypeptide Y4 Receptor J. Neurosci., February 15, 2003; 23(4): 1487 - 1497. [Abstract] [Full Text] [PDF] |
||||